Overview

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood

Status:
Recruiting
Trial end date:
2023-06-12
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the effect of multiple doses of the strong CYP3A inhibitor and recommended Pglycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of a single dose of BI 1810631 in plasma following oral administration.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Itraconazole